

Federica SorÃ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6992491/publications.pdf>

Version: 2024-02-01

42
papers

505
citations

758635

12
h-index

752256

20
g-index

44
all docs

44
docs citations

44
times ranked

725
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
2	Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. <i>Bone Marrow Transplantation</i> , 2022, 57, 532-537.	1.3	6
3	Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics. <i>Hematological Oncology</i> , 2022, 40, 469-474.	0.8	4
4	Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. <i>Bone Marrow Transplantation</i> , 2022, 57, 837-839.	1.3	4
5	BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. <i>Leukemia</i> , 2021, 35, 2102-2107.	3.3	8
6	Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen. <i>American Journal of Hematology</i> , 2021, 96, 234-240.	2.0	14
7	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	0.6	10
8	Second haploidentical stem cell transplantation for primary graft failure. <i>Bone Marrow Transplantation</i> , 2021, 56, 1291-1296.	1.3	14
9	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 271-279.	1.2	4
10	Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia: Case reports and literature review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29044.	0.8	7
11	Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021. <i>Frontiers in Immunology</i> , 2021, 12, 637512.	2.2	9
12	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171.	1.3	6
13	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021, 60, 1527-1533.	0.8	2
14	Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag. <i>Medicina (Lithuania)</i> , 2021, 57, 1326.	0.8	1
15	SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102881.	0.5	6
16	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020, 135, 534-541.	0.6	61
17	Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML". <i>Blood</i> , 2020, 136, 35-36.	0.6	1
18	Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting. <i>Blood</i> , 2020, 136, 12-13.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
20	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	0.8	17
21	â€œSecondary chronic myeloid leukemiaâ€™: comparison between patients previously exposed or not to chemo- and/or radiotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3584-3586.	0.6	5
22	Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy. <i>Annals of Hematology</i> , 2019, 98, 2609-2611.	0.8	13
23	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	1.7	58
24	HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1340-1342.	0.6	16
25	Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation. <i>Blood</i> , 2019, 134, 2919-2919.	0.6	2
26	Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors. <i>Blood</i> , 2019, 134, 1649-1649.	0.6	7
27	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	0.8	32
28	Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome. <i>Hematological Oncology</i> , 2018, 36, 392-398.	0.8	6
29	Role of flowâ€cytometric immunophenotyping in prediction of <i>BCR/ABL1</i> gene rearrangement in adult Bâ€cell acute lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 468-476.	0.7	14
30	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018, 132, 5438-5438.	0.6	0
31	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	1.7	15
32	Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 993-995.	0.6	10
33	Frontline Dasatinib Treatment in a â€œReal-Lifeâ€ Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540.	2.3	24
34	Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy. <i>Blood</i> , 2016, 128, 942-942.	0.6	2
35	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	0.8	24
36	the Polymorphisms on Chromosome 9p21 Play a Role in the Risk for Cardiovascular Events in Chronic Myeloid Leukemia Patients?. <i>Blood</i> , 2016, 128, 5100-5100.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. <i>Blood</i> , 2016, 128, 3078-3078.	0.6	0
38	Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. <i>Leukemia and Lymphoma</i> , 2015, 56, 2841-2846.	0.6	11
39	Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2014, 55, 2958-2960.	0.6	7
40	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. <i>Drugs and Aging</i> , 2013, 30, 629-637.	1.3	36
41	Outcome of concurrent acute myeloid leukemia and granulocytic sarcoma: three clinical cases and a review of the literature. <i>Comparative Clinical Pathology</i> , 2012, 21, 725-730.	0.3	0
42	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011, 35, 1164-1169.	0.4	28